Open AccessPB2146: A PHASE 2, OPEN‐LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA‐R) IN PREVIOUSLY UNTREATED UNFIT/FRAIL PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (LOTIS‐9)
Author(s) -
Westin J.,
Burke J. M.,
Chapman A. E.,
Kilavuz T.,
Xu C.,
Shmuely Y.,
Radford J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000851416.21855.57
Subject(s) - medicine , rituximab , oncology , diffuse large b cell lymphoma , population , vincristine , chop , lymphoma , cyclophosphamide , chemotherapy , environmental health